Recent Finacing
Recent Raise
Bryleos is a clinical-stage therapeutics company developing BNAD101, a patent-pending oral NAD+ formulation shown in a proof-of-concept study to raise intracellular NAD within five days.
Focus Areas
Total Raised
Funding round
See the team members at Bryleos.
